Outcomes from COVID-19 Clinical Trials in Hospitalized Patients
Seeking the Truth That Matters

The coronavirus disease (COVID-19) pandemic has resulted in remarkable progress in understanding the disease through research and innovation at a pace far faster than possible pre-2020. For clinical trials, a key challenge has been the trade-off between “quick” answers versus those that have a longer time horizon and require more data collection. Understanding the implications of these approaches is critical when the aim is measuring sustained patient recovery.

In this issue of the Journal, Douin and colleagues (pp. 730–739) highlight the potential pitfalls of using hospital discharge as an endpoint in trials by comparing several approaches to outcome measurement (1). The authors compared the performance of three different measures of recovery with different time horizons. Their aim was to establish whether studies that considered discharge from hospital alone as a successful outcome might under-represent important outcomes occurring in the following weeks such as hospital readmission or post-discharge death.

References
1. Gerayeli FV, Milne S, Cheung C, Li X, Yang CWT, Tam A, et al. COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine 2021;33:100789.
2. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430–436.
3. Aveyard P, Gao M, Lindson N, Hartmann-Boyce J, Watkinson P, Young D, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med 2021;9:909–923.
4. Guo-Parke H, Linden D, Mousnier A, Scott IC, Killick H, Bothwick LA, et al. Altered differentiation and inflammation profiles contribute to enhanced innate responses in severe COPD epithelium to rhinovirus infection. Front Med (Lausanne) 2022;9:741989.
5. Johansen MD, Mahbub RM, Idrees S, Nguyen DH, Miemczyk S, Pathinayake P, et al. Increased SARS-CoV-2 infection, protease, and inflammatory responses in chronic obstructive pulmonary disease primary bronchial epithelial cells defined with single-cell RNA sequencing. Am J Respir Crit Care Med 2022;206:712–729.
6. Mulay A, Konda B, Garcia G Jr, Yao C, Bell S, Villaboa JM, et al. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. Cell Rep 2021;35:109055.
7. Agbowuro AA, Huston WM, Gamble AB, Tyndall JDA. Proteases and protease inhibitors in infectious diseases. Med Res Rev 2018;38:1295–1331.
8. Baggen J, Vanstreefs E, Jansen S, Daelemans D. Cellular host factors for SARS-CoV-2 infection. Nat Microbiol 2021;6:1219–1232.
9. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271–280.e8.
10. Jaimies JA, Millet JK, Whittaker GR. Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site. iScience 2020;23:101212.
11. Ji HL, Zhao R, Matalon S, Matthay MA. Elevated Plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev 2020;100:1065–1075.
12. Rosendale E, Mihai IS, Becker M, Das D, Frängsmyr L, Persson BD, et al. Seroine protease inhibitors restrict host susceptibility to SARS-CoV-2 infections. mBio 2022;13:e0089222.
13. Yang H, Yang J. A review of the latest research on Mpro targeting SARS-COV inhibitors. RSC Med Chem 2021;12:1026–1036.
14. Chapman KR, Burdon JGW, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, et al.; RAPID Trial Study Group. Intravenous augmentation treatment and lung density in severe α-1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015;386:360–368.
15. Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibilia O, et al.; WILLOW Investigators. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med 2020;383:2127–2137.

Copyright © 2022 by the American Thoracic Society

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern (dgern@ thoracic.org).

Originally Published in Press as DOI: 10.1164/rccm.202205-0907ED on May 24, 2022

Editorial

The use of protease inhibitors to ameliorate lung disease has had a difficult history with limited success to date. However, recent studies have shown more success including the use of α-1-antitrypsin to slow the progression of emphysema in patients with α-1-antitrypsin deficiency (RAPID trial) (14) and the use of the cathepsin C inhibitor, brensocatib, which has shown some success in patients with bronchiectasis (15). In conclusion, future therapeutic strategies to treat COVID-19 infection could incorporate the use of viral and host-directed protease inhibitors, and the development, and repurposing, of protease inhibitors to this end should be a focus of COVID-19 treatment strategies.
The authors reanalyzed data for 850 patients from three international clinical trials of monoclonal antibodies for treating COVID-19 conducted on the TICO/ACTIV-3 (Therapeutics for Inpatients with COVID-19/Accelerating COVID-19 Therapeutic Interventions and Vaccines-3) trial platform (2). None of the included trials demonstrated intervention efficacy, so data were pooled for a cohort analysis.

The three different definitions of recovery were described as “hospital discharge,” “comprehensive,” and “TICO” approaches. The “hospital discharge” definition was “discharged home alive within 90 days of enrollment” with time to recovery the time to hospital discharge. For the “comprehensive” definition, patients had to be alive and at home by Day 90, with time to recovery the time to last discharge home before Day 90. The “TICO” approach required patients to be at home for 14 consecutive days within the first 90 days to be termed recovered, with time to recovery the time from enrolment to the first day of the first 14-day period at home. Unrecovered patients were censored at 90 days. Recovery was considered discordant between these definitions if the time between enrolment and recovery differed for a given patient.

The comprehensive approach identified 20% of patients as discordant with the hospital discharge definition. The TICO definition captured 62% of these as nonrecovered, similar to the comprehensive approach. The most frequent reasons for discordance between hospital discharge and comprehensive definitions were hospital readmission (74%), discharge to a nonhome location (33%), or death (14%) and these were noted to be early events occurring within 2–3 weeks of hospital discharge. The authors thoughtfully considered how unrecovered patients are treated in survival analyses for each definition. Missing data, which of relevance was most prevalent for the comprehensive approach, was appropriately imputed, and a sensitivity analysis suggested this did not impact on the findings. The authors propose that the TICO measure might balance capturing important post-discharge outcomes “missed” using hospital discharge with the burden of longer post-hospital follow-up. The data indicate that collecting data for the first 3–4 weeks after discharge would capture most discordant events.

The study reminds us that using different outcome measures, even based on timing, can potentially generate different results in clinical trials. During the COVID pandemic, core outcomes sets (COS) were proposed for hospitalized adult COVID-19 trials by several independent groups (3–6). Most were registered with the Core Outcome Measures in Effectiveness Trials initiative and, uniquely, groups rapidly collaborated to agree to a “meta-COS” unifying the recommendations from individual projects (7). Of relevance to Douin and colleagues’ work, all-cause hospital mortality was the agreed core outcome, with a recommendation to measure time to death. The other key outcome was the type of respiratory support required, another hospital-based outcome. These outcomes have been used in most interventional trials during the pandemic. Several trials, for example the early remdesivir trials (8), nuanced these outcomes by creating categoric ordinal scales at time points post-randomization, usually in hospital. Most were derived through expert consensus and lacked formal validation. Comparing distributions of these outcomes could increase statistical power to detect differences compared with dichotomous measures, again potentially providing quicker answers. Alternatively, or in addition, cut-offs on the scales were used to dichotomise recovery status. These approaches are effectively “intermediate” outcomes and their validity relies on them accurately predicting sustained patient recovery. For hospitalized COVID-19 patients, defining “sustained recovery” probably depends partly on perspective. A clinician may be satisfied with hospital survival, especially if this represents the outcome from their care. In contrast, for patients, their perspective will include more patient-reported outcome measures, and a recent COS consensus process recommended “recovery” include the absence of symptoms, ability to perform usual daily activities, and a return to previous state of health and mind, suggesting the use of a Lickert scale for measurement (9). During the pandemic, the health service provider perspective has been especially relevant because minimizing overall time in hospital has been critical due to staff and bed shortages.

The analysis by Douin and colleagues provides key insights that question the reliance on hospital survival alone. First, the 20% discordance between hospital survival and a 90-day “comprehensive” outcome of sustained recovery clearly shows that hospital survival misses many important events. Second, most discordant events were early rehospitalizations indicating incomplete recovery and further hospital resource use. Finally, discordant patients were older, more comorbid, and COVID antibody negative which are all risk factors for poorer outcomes. Recording a “positive” rather than “negative” outcome for these higher risk patients could misrepresent true sustained recovery, and inflate estimated clinical effects based on hospital-based outcome alone. This might partly explain why smaller efficacy trials using hospital-based outcomes found apparently meaningful benefit, while larger effectiveness trials demonstrated smaller or no effect, as was the case for remdesivir (10).

The work of Douin and colleagues provides further learning from the COVID-19 pandemic for current and future research, especially when there is a need for time critical results. The findings highlight the need to balance the “quick answer approach” with the importance of including outcomes that matter to patients and service providers after discharge from hospital, even if gathering these data takes more time and effort during periods of system-level stress.

Author disclosures are available with the text of this article at www.atsjournals.org.

David M. Griffith, M.D.
Timothy S. Walsh, M.D.
Usher Institute
University of Edinburgh
Edinburgh, United Kingdom

ORCID IDs: 0000-0001-9500-241X (D.M.G.); 0000-0002-3590-8540 (T.S.W.).

References
1. Douin DJ, Siegel L, Grandits G, Phillips A, Aggarwal NR, Baker J, et al.; ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Evaluating primary endpoints for COVID-19 therapeutic trials to assess recovery. Am J Respir Crit Care Med 2022;206:730–739.
2. Murray DD, Babiker AG, Baker JV, Barkauskas CE, Brown SM, Chang CC, et al. Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2
antiviral agents: therapeutics for inpatients with COVID-19 (TICO/ACTIV-3). Clin Trials 2022;19:52–61.
3. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020;20:e192–e197.
4. Jin X, Pang B, Zhang J, Liu Q, Yang Z, Feng J, et al. Core outcome set for clinical trials on coronavirus disease 2019 (COS-COVID). Engineering (Beijing) 2020;6:1147–1152.
5. Qiu R, Zhao C, Liang T, Hao X, Huang Y, Zhang X, et al. Core outcome set for clinical trials of COVID-19 based on traditional Chinese and Western medicine. Front Pharmacol 2020;11:781.
6. Tong A, Elliott JH, Azevedo LC, Baumgart A, Bersten A, Cervantes L, et al.; COVID-19-Core Outcomes Set (COS) Workshop Investigators. Core outcomes set for trials in people with coronavirus disease 2019. Crit Care Med 2020;48:1622–1635.
7. https://www.comet-initiative.org/studies/details/1538; accessed 2022 May 12.
8. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al.; ACTTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med 2020;383:1813–1826.
9. Tong A, Baumgart A, Evangelidis N, Vicelli AK, Carter SA, Azevedo LC, et al.; COVID-19-Core Outcomes Set Investigators. Core outcome measures for trials in people with coronavirus disease 2019: respiratory failure, multiorgan failure, shortness of breath, and recovery. Crit Care Med 2021;49:503–516.
10. WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 2022;399:1941–1953.

**Anabolic Resistance: An Uncomfortable Truth for Clinical Trials in Preventing Intensive Care–acquired Weakness and Physical Functional Impairment**

Acute muscle wasting occurs rapidly in critically ill patients and results in long-lasting physical functional impairment, at substantial physical, emotional, and economic cost to patients, families, and society. After critical illness, patients struggle to regain muscle mass, and rehabilitation strategies have yet to be demonstrated to be successful, emphasizing the need for primary prevention to minimize muscle loss during the acute phase. Loss of muscle mass is the result of altered protein homeostasis, which is in turn underpinned by intramuscular inflammation and bioenergetic failure from altered substrate use (1, 2). Given the scale of the clinical problem, and the lack of therapeutic options, maintaining muscle mass and associated physical function is of increasing interest to clinical trialists and funding bodies (3). One frequently discussed possibility is to increase protein intake to prevent the loss of muscle protein, but trials have in general not been successful. Designing appropriate interventional studies requires additional physiological and mechanistic knowledge, such as the ability of skeletal muscle to both receive and respond to such interventions. The recent study by Chapple and colleagues (pp. 740–749) in this issue of the *Journal supplies exactly this (4).*

Dynamic measurements of physiological processes are challenging to both observe and quantify. Molecular medicine remains an imperfect window, with multiple competing and interacting intracellular pathways to account for, in addition to the entropic requirements of these processes. Stable isotope tracer methodology has existed for almost eight decades and has over time become increasingly sophisticated as a summative measure of physiological processes (5). This technology, which uses stable isotope–labeled metabolites, is the only method available to quantify the flux or rate of metabolic and physiological pathways *in vivo* in humans, without any risk for the subjects because of the use of nonradioactive isotopes that are already naturally occurring. Challenges with this technology are the relatively high costs for material and analyses and the required expertise in mass spectrometry and kinetic modeling. Chapple and colleagues (4) have used this technology by combining different stable isotope tracers of amino acid and protein metabolism in an innovative way, quantifying several components of protein metabolism at the same time.

Chapple and colleagues (4) offer a unique physiological observational study filling two important gaps in knowledge of relevance to current trials of nutritional protein supplementation in critically ill patients. First, is amino acid absorption impaired as measured by gut lumen to central circulation flux? Second, is the dynamic capacity of skeletal muscle to respond to nutritional amino acids impaired? Stable isotope infusions into two compartments (luminal and central circulation) were performed, and incorporation of amino acids into a third compartment (skeletal muscle) was measured, encompassing the entirety of the nutritional amino acid supplementation pathway and its potential downstream impact.

Three distinct but related observations were made. First, duodenum-administered protein absorption into the central circulation was not impaired in critically ill patients compared with healthy control subjects over 6 hours. Second, the response of the whole-body protein balance to an enteral protein feed was similar in patients and control subjects, despite overall higher whole-body protein turnover (protein breakdown and synthesis) in the patients. Last, although fasting muscle protein synthesis rates did not differ between groups, a blunted response in muscle protein synthesis was seen in critically ill patients after intraduodenal protein administration. This resulted in 60% less nutritional protein being incorporated into skeletal muscle in critically ill patients compared with healthy control subjects.